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Helminths and Immunological Tolerance
Chris J.C. Johnston,1,2 Henry J. McSorley,1 Stephen M. Anderton,2 Stephen J. Wigmore,2
and Rick M. Maizels1,3
Current immunosuppression regimens for solid-organ transplantation have shown disappointing efficacy in the
prevention of chronic allograft rejection and carry unacceptable risks including toxicity, neoplasia, and life-
threatening infection. Achievement of immunological tolerance (long-term antigen unresponsiveness in an immu-
nocompetent host) presents the exciting prospect of freedom from immunosuppression for transplant recipients. It is
now 60 years since the first demonstration of immunological tolerance in animal models of transplantation, but
translation into routine clinical practice remains elusive. Helminth parasites may provide novel strategies toward
achieving this goal. Helminths are remarkably successful parasites: they currently infect more than one quarter of
the world’s population. It is now well established that the parasites’ success is the result of active immunomodulation
of their hosts’ immune response. Although this primarily secures ongoing survival of the parasites, helminth-induced
immunomodulation can also have a number of benefits for the host. Significant reductions in the prevalence of al-
lergy and autoimmune conditions among helminth-infected populations are well recognized and there is now a
significant body of evidence to suggest that harmful immune responses to alloantigens may be abrogated as well.
Here, we review all existing studies of helminth infection and transplantation, explore the mechanisms involved, and
discuss possible avenues for future translation to clinical practice.
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(Transplantation 2014;97: 127Y132)
Successful organ transplantation requires negotiation of anumber of complex immunologic barriers. In addition
to cell-mediated rejection resulting from mismatching of
major and minor histocompatibility complexes (1), innate
immune responses are invariably stimulated by a combi-
nation of surgery itself and organ damage resulting from
ischemia and reperfusion (2). Ever-increasing demand for
organ transplantation has unfortunately coincided with a
steady decline in the availability of donor organs in recent
decades (3). This has necessitated amended strategies to ex-
pand the donor pool that can result in donor organs of a lesser
quality and/or greater degrees of immunologic mismatch (3).
Despite this, solid-organ transplantation has become
the standard of care for numerous disease processes that
result in organ failure. Advances in surgical techniques and
immunosuppressive regimens mean that excellent short-
term to medium-term graft survival has now come to be
expected. However, recent scrutiny of long-term allograft
survival data reveals that considerable improvements in the
incidence and management of acute rejection have not been
reflected in improved long-term outcomes (4). For living-
donor kidney transplant recipients in the United States,
organ graft survival half-life is almost unchanged (in 2005,
this was 11.9 years compared with 11.4 years in 1989) (5). A
similar disparity in short-term and long-term survival rates
has also been seen in liver, lung, heart, intestine, and pan-
creas transplantation (6).
Current immunosuppression regimens used in solid-
organ transplantation carry significant risks of toxicity, in-
fection (7), and neoplasia (8). The incidence of neoplastic
disorders such as posttransplantation lymphoprolifera-
tive disease, in particular, relates more to the intensity of
immunosuppression than the specific agent used (1). All
of these factors have fuelled the long-held ambition for
allograft tolerance, defined as durable antigen-specific un-
responsiveness in an immunocompetent host (9).
Despite the achievement of experimental murine al-
lograft tolerance 60 years ago (10), translation to the clinical
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setting has been frustratingly slow. Recent developments in
the understanding of regulatory cell populations have, how-
ever, allowed some ground for optimism (11). In particular, a
recent trial of combining kidney transplantation with a si-
multaneous bone marrow transplant from single human
leukocyte antigen (HLA)Ymismatched donors has allowed for
successful withdrawal of all immunosuppression in four of
five patients (12). With this technique, patients developed
transient mixed chimerism and lasting specific alloantigen
unresponsiveness as a result. With the same technique,
Scandling et al. have independently demonstrated similarly
impressive outcomes with HLA-matched kidney transplan-
tation: from a cohort of 16 patients, 8 have achieved rejection-
free avoidance of immunosuppressive medication for more
than 1 year, and a further 4 patients are in the process of
withdrawal from medication (13). Although many would
consider simultaneous bone marrow transplantation to pres-
ent an unacceptable level of complexity and risk in the
pursuit of solid-organ allograft tolerance (9), this impor-
tant study has shown lasting intragraft regulatory cell pop-
ulations and the successful allograft tolerance this can achieve
in a clinical setting.
The ability of regulatory T cells (Treg) to mediate allo-
graft tolerance in murine models is now well recognized (14).
Expectations of successful translation of Treg therapy into the
clinical setting have been high and preliminary clinical trials
have now been completed in graft-versus-host disease (15)
and hematopoietic stem cell transplantation (16) with modest
but encouraging results. However, a number of obstacles
and concerns persist. First, Good Manufacturing Practice-
compliant ex vivo expansion of Tregs for subsequent reinfu-
sion is a highly specialized process at a cost of approximately
$40,000 per patient (17). Second, difficulty in identifying
regulatory cell populations for purification and ensuring that
they do not convert away from the regulatory phenotype
presents the possibility of harm caused by inadvertent infu-
sion of expanded effector T-cell populations (resulting in en-
hanced rejection or autoimmunity) (18). Finally, the specificity
of Treg-induced immunosuppression is uncertain and may
therefore present a risk of infection or neoplasia similar to that
of current global immunosuppression regimens. Although
results from early studies provide some degree of reassurance
in this regard (19), analysis of long-term clinical safety data is
still awaited.
Helminth Infections and Host Immunity
Helminth worms are particularly successful parasites; as
recently as 1940, the prevalence of infection in children in
some rural areas of the United States was as high as 70% (20)
and the current rate of chronic infection stands at more than
one quarter of the world’s population (21). Helminths’ success
is now recognized to be the result of active modulation of their
hosts’ immune response (21). In addition to facilitating
chronic infection, parasite-derived dampening of the host
systemic immune response also results in reduced reactivity to
unrelated ‘‘bystander’’ allergens and autoantigens or alloanti-
gens. In many cases, this effect is of some considerable benefit
to the host. Recent studies have shown abrogation of multiple
disease processes in the presence of helminth infection, in-
cluding allergic airway inflammation, encephalitis, inflam-
matory bowel disease, rheumatoid arthritis, and type I
diabetes in experimental models (22). Epidemiologically, it is
well established that the prevalence of allergic and autoim-
mune disorders is higher in developed countries compared
with developing nations. Recent cohort studies investigating
allergic responses in children demonstrated reduced skin
responses to antigen testing in helminth-infected subjects
compared with controls and found that this effect was
eliminated after clearance of infections with antihelminthic
therapy (22). Similarly, patients with multiple sclerosis in
Argentina who adventitiously acquired helminth infec-
tions were found to stay in remission but relapsed after
antihelminthic drug treatment (23). A recent phase I trial of
experimental helminth infection with Trichuris suis as a
therapy for Crohn’s disease revealed no adverse effects (in 29
patients) and showed promising considerable reductions in
disease severity scores (24). Large-scale Good Manufacturing
PracticeYcompliant production of T. suis for clinical use has
TABLE 1. Published studies reporting prolonged allograft survival in humans or laboratory animals in helminth-infected
hosts, or in animals given helminth-derived products.
Authors Parasite Allograft model Graft prolongation P
Aboul-Enein et al. (41) Schistosoma mansoni Human skin 2.21 0.001
Hepiretihan et al. (32) Echinococcus multilocularis Rat heart 2.04 G0.05
Li et al. (31) E. multilocularis Rat liver 1.57 G0.05
Liwski et al. (34) Nippostrongylus brasiliensis Mouse heart 2.80 G0.03
Ledingham et al. (33) N. brasiliensis Rat kidney 3.30 G0.001
Araujo et al. (42) Nippostrongylus NES Rat kidney 2.22 G0.001
S. mansoni Mouse skin 1.5 G0.001
Svet-Moldavsky et al. (43) Trichinella spiralis Mouse skin 2.13
Faubert and Tanner (44) T. spiralis Mouse skin 1.89 G0.001
Chimyshkyan et al. (45) Infected mouse serum Mouse skin 1.67
T. spiralis Mouse skin 2.48 G0.001
Alkarmi et al. (46) Trichinella pseudospiralis Mouse skin 3.57 V
T. pseudospiralis extract Mouse skin 2.0 V
T. spiralis Mouse skin 3.57 V
T. spiralis extract Mouse skin 2.43 V
128 www.transplantjournal.com Transplantation & Volume 97, Number 2, January 27, 2014
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
been approved by the U.S. Food and Drug Administration
and a number of multicenter randomized controlled trials
have commenced (25). In the absence of a corresponding
analysis of allograft survival in helminth infected hosts, we
performed a publication search (Fig. 1) and report here a
synthesis of the relevant literature.
Echinococcus Tapeworms
The metacestode Echinococcus multilocularis (Em) is
endemic among foxes in many parts of Europe and China
such that humans can be affected as accidental hosts. In-
fection can result in severe disease with a clinical course
resembling that of a malignant primary liver tumor (hepa-
tocellular carcinoma) (26). Radical surgical resection of liver
lesions has been shown to be effective in improving survival
and orthotopic liver transplantation is now largely accepted
as appropriate treatment for advanced disease (27). Disease
progression caused by the parasite has been found to ad-
vance rapidly in the presence of host immunosuppression
either as a result of medication (1, 28) or HIV infection (2, 29).
This finding led to guidelines recommending reduced im-
munosuppression regimens after liver transplantation for
Em (30) and long-term follow-up reported unexpectedly
satisfactory tolerance of the allografts (3, 27). Tao et al. have
subsequently corroborated this finding in an experimental
rat model of liver transplantation with Em infection (3, 31)
(Table 1). In this study, survival after orthotopic liver
transplantation found to be significantly prolonged for
Em-infected rats compared with naBve controls (15.5T3.9 vs.
9.9T2.3 days; PG0.05). The Em-infected group was also found
to have reduced CD4+, CD8+, and CD28+ T-cell populations
in peripheral blood, raised serum interleukin (IL)-10 levels,
and reduced histologic liver allograft rejection scores, all of
which reached statistical significance (PG0.05) (4, 31). More
recently, Hepiretihan et al. have shown a that Em infection
exerts a similar protective effect against rejection of rat heart
allografts (16.2T3.2 vs. 7.9T1.9 days) (5, 32). This was asso-
ciated with a reduction in graft-infiltrating CD8+ lympho-
cytes and a shift toward a Th2 cytokine profile in the serum
of peripheral blood. In the clinical setting, eradication of Em
infection usually proves impossible. It therefore remains as
yet unclear as to whether graft protection is afforded by an
ongoing influence of the parasite or as the result of a Th2
cytokine environment at the time of alloantigen presentation.
Nippostrongylus Roundworms
Beneficial enhancement of allograft tolerance in the
presence of helminth infection has now been demonstrated
with a number of parasite species and does not seem to be
restricted to specific organs or host species (Table 1). In
1996, Ledingham et al. demonstrated marked improvement
in the survival of kidney allografts in rats infected with the
gastrointestinal nematode, Nippostrongylus brasiliensis (Nb),
or inoculated with its secretory products compared with
naBve controls (32T10, 21T4.6, and 9.7T1.2 days, respectively;
PG0.001) (6, 33). Representative histologic examination 5 days
after transplantation showed a dramatic reduction of graft
cellular infiltration in the Nb-infected group and this find-
ing was supported quantitatively with flow cytometric anal-
ysis of digested allograft single-cell suspensions (84% and
FIGURE 1. Search strategy.
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81% reduction of CD8+ and CD4+ lymphocytes, respectively).
Although the graft protection afforded by Nippostrongylus
excretory-secretory products (NES) was less pronounced, the
pharmacokinetic profile of the active mediator(s) in NES
is unknown and this may therefore be a purely dose-
dependent difference.
The same group later showed similar (2.8-fold) graft
protection in a mouse cardiac allograft model (7, 34). Nb
infection is known to induce a strong Th2 response in its
host (8, 35), leading those authors to hypothesize that po-
larization away from Th1-mediated allograft rejection may
afford allograft protection. Nb usually achieves only a lim-
ited infection in rodentsVmost mouse strains can clear the
infection within 10 days of inoculation with third-stage
larvae (1, 35). The finding that mouse heart allografts can
survive for considerably longer than the period of infection
(9, 34), presents the exciting therapeutic prospect that graft
protection is afforded by T-cell ‘‘phenotype switching’’ at
the time of alloantigen presentation rather than a mecha-
nism dependent on persisting parasite infection. Enzyme-
linked immunosorbent assay analysis of mixed lymphocyte
reactions supports this hypothesis in demonstrating a Th2
cytokine profile (IL-4 and IL-6) in alloreactive lympho-
cytes from Nb-infected mice compared with naBve con-
trols (34, 36).
Schistosome Flukes
Schistosoma is a genus of blood-borne trematode with
a current prevalence of infection estimated at more than
200 million people worldwide (10, 37). In light of the very
widespread prevalence of schistosomiasis and the diminishing
supply of suitable cadaveric donor organs for transplantation,
a number of human liver (11, 38, 39) and kidney (12, 40)
transplants in patients with clinical schistosomiasis have been
performed (donor and recipient, donor alone, and recipient
alone). No attempts at reducing immunosuppression or
analyzing differences in rejection rates have as yet been
reported. However, one remarkable study has looked at the
differential rejection of full-thickness skin grafts in Egyptian
patients with established schistosomiasis compared with
healthy volunteers. Aboul-Enein et al. (9, 41) recruited 19
patients with advanced Schistosoma mansoni infection and
16 parasite-free volunteer controls. Then, 2.5-cm-diameter
full-thickness skin grafts were applied to the volar forearm.
Two grafts were performed for each patient: one ABO-
matched allograft from a noninfected donor and one auto-
graft control. Grafts were assessed daily for signs for rejection
and rejection was then confirmed histologically. The control
group rejected their allografts after a mean of 10.06T3.21 days.
Of the Schistosoma-infected patients, in 16 cases, rejection
occurred after a mean of 22.25T6.46 days. The remaining
three infected patients showed no signs of rejection 60 days
after the grafting procedure. Notably, the HLA status of do-
nors and recipients was unknown in this study; therefore, the
three cases of long-term graft tolerance may well be the result
of coincidental HLA matching. In spite of this significant ca-
veat, the difference in rejection times between the two groups
was highly significant (PG0.001) and therefore unlikely to be
the result of differences in HLA matching alone.
Allograft protection with Schistosoma infection has
previously been shown in a murine experimental model. In
1977, Araujo et al. found a highly significant difference in the
rejection of fully allogeneic skin grafts in S. mansoniYinfected
versus naBve recipient mice (14, 42). No difference was found
after 30 days of infection, but for grafts performed after 60 days
of infection, infected recipients tolerated their grafts for an
average of 50% longer than naBve controls. A strongly positive
correlation between graft survival and the number of live
parasites remaining in the recipient was also seen (r=0.096).
Trichinella
Finally, murine experimental models of other helminth
species have also demonstrated enhanced tolerance of skin
allografts. Trichinella spiralis is a small nematode that encysts
in mammalian muscle and can affect humans who consume
infected meat. Suppression of skin allograft rejection in mice
infested with Trichinella was first described by Svet-Moldavsky
et al. in 1969 (15, 43) and subsequently confirmed by Faubert
and Tanner (16, 44) and Chimyshkyan et al. (18, 45). In 1995,
Alkarmi et al. performed fully allogeneic skin grafts (C57BL/6
to BALB/c recipients and vice versa) on multiple groups of
mice at varying time points after infection (17, 46). Graft
protection was found to be critically dependent on the timing
of skin transplantation in relation to initial infection and a
maximum effect of 3.5-fold prolongation of graft survival was
found when the transplants were performed 3 days after initial
infection. Repeated intraperitoneal injection of parasite se-
cretions (culture supernatants) replicated the effect of active
infection in a dose-dependent fashion with an observed
maximum twofold prolongation in graft survival (18, 46).
Evolution of Regulation
Coevolution of helminths and humans over millions of
years (19, 47) has resulted in multiple effective mechanisms
of immunomodulation, which may individually or in com-
bination be responsible for the prolongation of allograft
survival. Certainly, it is now clear that helminths act via
multiple distinct and synergistic pathways to down-regulate
host immunity. Expansion of Treg populations in response
to helminth infections such as Heligmosomoides polygyrus
(20, 48) and S. mansoni (21, 49) is one well-recognized mech-
anism, but the same parasites can also engender immuno-
suppressive activity in B-cell populations as well as modified
dendritic cell and macrophage populations (21, 22).
In this context, it is possible that therapeutic extension
of graft survival would also require more than one particular
immunomodulatory pathway. With respect to Treg expan-
sion, exogenous IL-2:anti-IL-2 antibody complex is a potent
short-term stimulant of Treg populations, which can effect
long-term tolerance of allogeneic islet grafts in the absence
of immunosuppression (22, 50). However, multiple at-
tempts to achieve similar tolerance of allogeneic skin grafts
(BALB/c to C57BL/6) have failed (23, 51). It is well known
in the experimental and clinical setting that tolerance of skin
allografts presents a particular challenge (compared with the
solid-organ transplants of heart, liver, or kidney). Important
factors to overcome are likely to be the large proportion of
resident dendritic cells in skin (24, 51) and more potent
Toll-like receptor stimulation by colonizing microbes (25, 52).
Failure of IL-2:anti-IL-2 complexes to achieve the same level
of protection of fully allogeneic skin grafts against rejection
(26, 51) that is seen in Schistosoma infection (27, 41) strongly
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suggests that Treg-independent mechanisms also play a criti-
cal role in helminth-derived allograft protection.
CONCLUSIONS
Enhanced allograft tolerance with helminth infection
has now been demonstrated in multiple species across mul-
tiple organ allograft models (mouse heart and skin; rat heart,
liver, and kidney). These experimental data are consistent with
historical results of skin grafting in established human schis-
tosomiasis and supported by more recent anecdotal sugges-
tions of reduced immunosuppression requirement after liver
transplantation for human Echinococcus infection (27). Thus,
the possibility can now be entertained of including specific
live (nonpathogenic) helminth infection, or defined products
from immunoregulatory helminths, in future transplantation
protocols. Ongoing trials of live T. suis therapy in inflamma-
tory bowel disease (25) are keenly awaited as potential path-
finding studies for translation of this concept to the clinic.
There are indeed multiple potential opportunities for
helminthic and helminth product therapy in transplanta-
tion. The most promising is with living-donor transplanta-
tion, whereupon a course of helminthic therapy may be
commenced before the time of transplantation, allowing
alloantigen presentation to occur in a tolerogenic environ-
ment (either at the time of the transplantation itself or with
known defined alloantigens beforehand). Although treat-
ment with active helminth infection has been shown to be a
safe therapeutic approach (25), reports of mild gastrointes-
tinal side effects do exist and might limit patient accept-
ability (53). Identification and synthetic production of the
active compounds within helminthic secretions for novel
pharmaceutical intervention is a definitive goal and the fo-
cus of much attention (54). Measured against current trans-
plant immunosuppression regimens with multiple serious
adverse effects and inadequate long-term organ protection
against rejection, therapy with helminths or their products
presents the exciting opportunity of a safe, effective, and long-
overdue alternative.
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